H 151 - ≥98%(HPLC), high purity , CAS No.941987-60-6, Antagonist of stimulator of interferon response cGAMP interactor 1

1 Citations
Item Number
H287635
Grouped product items
SKUSizeAvailabilityPrice Qty
H287635-5mg
5mg
In stock
$44.90
H287635-10mg
10mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$69.90
H287635-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$279.90
H287635-100mg
100mg
In stock
$429.90
H287635-250mg
250mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$799.90

STING antagonist

Basic Description

Synonyms1-(4-ethylphenyl)-3-(1H-indol-3-yl)urea | 3-(4-ethylphenyl)-1-(1H-indol-3-yl)urea | N-(4-ethylphenyl)-N'-1H-indol-3-yl-urea | H-151
Specifications & PurityMoligand™, ≥98%(HPLC)
Biochemical and Physiological MechanismsH-151 is an irreversible antagonist of the stimulator of interferon genes (STING) protein, a central signalling component of the cytosolic DNA sensing pathway. Although STING is a vital component of the innate immune pathways, it has also been shown to ha
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeANTAGONIST
Mechanism of actionAntagonist of stimulator of interferon response cGAMP interactor 1

Associated Targets(Human)

TMEM173 Tchem Stimulator of interferon genes protein (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HFF (3142 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

MEF (1005 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Sting1 Stimulator of interferon genes protein (255 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Names and Identifiers

IUPAC Name 1-(4-ethylphenyl)-3-(1H-indol-3-yl)urea
INCHI InChI=1S/C17H17N3O/c1-2-12-7-9-13(10-8-12)19-17(21)20-16-11-18-15-6-4-3-5-14(15)16/h3-11,18H,2H2,1H3,(H2,19,20,21)
InChi Key UJZDIKVQFMCLBE-UHFFFAOYSA-N
Canonical SMILES CCC1=CC=C(C=C1)NC(=O)NC2=CNC3=CC=CC=C32
Isomeric SMILES CCC1=CC=C(C=C1)NC(=O)NC2=CNC3=CC=CC=C32
PubChem CID 7616033
Molecular Weight 279.34

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

11 results found

Lot NumberCertificate TypeDateItem
J2120385Certificate of AnalysisAug 14, 2024 H287635
J2120383Certificate of AnalysisAug 09, 2024 H287635
D2423369Certificate of AnalysisApr 11, 2024 H287635
D2423371Certificate of AnalysisApr 11, 2024 H287635
D2423372Certificate of AnalysisApr 11, 2024 H287635
D2423373Certificate of AnalysisApr 11, 2024 H287635
D2423374Certificate of AnalysisApr 11, 2024 H287635
D2423375Certificate of AnalysisApr 11, 2024 H287635
D2423376Certificate of AnalysisApr 11, 2024 H287635
D2423377Certificate of AnalysisApr 11, 2024 H287635
D2315353Certificate of AnalysisJun 29, 2021 H287635

Show more⌵

Chemical and Physical Properties

SolubilityInsoluble in water,Dissolved in DMSO, maximum concentration (mg/ml): 125, maximum concentration (mm): 447.48 (ultrasonic treatment required)

Safety and Hazards(GHS)

Pictogram(s) GHS07
Signal Warning
Hazard Statements

H315:Causes skin irritation

H319:Causes serious eye irritation

H335:May cause respiratory irritation

Precautionary Statements

P261:Avoid breathing dust/fume/gas/mist/vapors/spray.

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

Related Documents

Citations of This Product

1. Xiaohua Xie, Xiaofeng Wu, Dongsheng Zhao, Ying Liu, Qiyue Du, Yitian Li, Yaping Xu, Yuhang Li, Yan Qiu, Yungang Yang.  (2023)  Fluvoxamine alleviates bleomycin-induced lung fibrosis via regulating the cGAS-STING pathway.  PHARMACOLOGICAL RESEARCH,  187  (106577).  [PMID:36435270]

References

1. Haag SM, Gulen MF, Reymond L, Gibelin A, Abrami L, Decout A, Heymann M, van der Goot FG, Turcatti G, Behrendt R et al..  (2018)  Targeting STING with covalent small-molecule inhibitors..  Nature,  559  (7713): (269-273).  [PMID:29973723]
2. Di Domizio J, Gulen MF, Saidoune F, Thacker VV, Yatim A, Sharma K, Nass T, Guenova E, Schaller M, Conrad C et al..  (2022)  The cGAS-STING pathway drives type I IFN immunopathology in COVID-19..  Nature,  129  (3): (589-97).  [PMID:35045565]
3. Xiaohua Xie, Xiaofeng Wu, Dongsheng Zhao, Ying Liu, Qiyue Du, Yitian Li, Yaping Xu, Yuhang Li, Yan Qiu, Yungang Yang.  (2023)  Fluvoxamine alleviates bleomycin-induced lung fibrosis via regulating the cGAS-STING pathway.  PHARMACOLOGICAL RESEARCH,  187  (106577).  [PMID:36435270]

Solution Calculators